Table 1. Descriptive characteristics for... | American Society of Hematology

Table 1.

Descriptive characteristics for patients with FL age <65 and ≥65 years

Characteristic	Patients age <65 years						Patients age ≥65 years
Characteristic	Total	Private, %	No insurance, %	Medicaid, %	Medicare, %	P	Total	Private, %	Medicare, %	P
Sex
Male	11 108	50.8	53.1	44.7	46	<.0001	9 727	51.6	45	<.0001
Female	11 025	49.2	46.9	55.3	54		11 492	48.4	55
Race/ethnicity
White	17 325	81	61.7	60.4	78.5	<.0001	18 121	82.3	85.9	<.0001
Hispanic	1 460	4.8	19.1	18	5.9		594	4	2.6
Black	1 349	5	11.1	13	7.8		780	4.5	3.6
Other	1 849	8.5	7.5	8	7.3		1 616	8.6	7.5
Unknown	150	0.7	0.6	0.6	0.5		108	0.7	0.5
Percent with no high school diploma
<7	6 247	31.6	15.8	11	17.8	<.0001	5 784	30.6	26.7	<.0001
7-12.9	7 420	34.6	26.3	29.9	31.3		7 450	34.6	35.2
13-20.9	5 137	21.9	27.8	29.1	28.3		5 106	21.7	24.4
>21	3 080	10.7	29.2	29.2	21.6		2 622	11.8	12.4
Unknown	249	1.2	0.9	0.8	1		257	1.3	1.2
B symptoms present
Yes	4 139	16.6	31.2	28.7	21.6	<.0001	3 206	14.2	15.3	.0688
No	16 309	75.5	63.1	66	70.4		15 993	77.6	75
Unknown	1 685	7.9	5.7	5.4	8		2 020	8.3	9.7
Stage
I/II	8 574	40	29.5	30.7	40.1	<.0001	9 105	43.8	42.8	.0813
III/IV	11 675	51.7	61.7	61.1	49.9		9 904	44.6	47
Unknown	1 884	8.4	8.8	8.2	9.9		2 210	11.6	10.2
Comorbidities
0	19 152	88.6	84.9	79.4	73.1	<.0001	16 422	80.1	77	.0002
1	2 436	9.7	12.3	15.6	19.7		3 605	15.6	17.2
≥2	545	1.8	2.8	5	7.2		1 192	4.3	5.8
Initial treatment
Systemic	13 838	61	71.7	71.6	62.9	<.0001	11 805	54.2	55.9	.0959
None	7 629	35.7	26.9	25.6	35.5		8 890	43.3	41.7
Days from diagnosis to treatment
0-14	8 264	37.9	35.3	36.5	34	.0002	7 439	34.2	35.2	.0412
15-30	3 342	15.1	14.6	15.2	15.7		3 041	12.8	14.6
>30	6 437	28.4	34.1	32.1	30.1		5 748	28.1	26.9
Unknown	4 090	18.7	16	16.2	20.2		4 991	24.9	23.3

Characteristic	Patients age <65 years						Patients age ≥65 years
Characteristic	Total	Private, %	No insurance, %	Medicaid, %	Medicare, %	P	Total	Private, %	Medicare, %	P
Sex
Male	11 108	50.8	53.1	44.7	46	<.0001	9 727	51.6	45	<.0001
Female	11 025	49.2	46.9	55.3	54		11 492	48.4	55
Race/ethnicity
White	17 325	81	61.7	60.4	78.5	<.0001	18 121	82.3	85.9	<.0001
Hispanic	1 460	4.8	19.1	18	5.9		594	4	2.6
Black	1 349	5	11.1	13	7.8		780	4.5	3.6
Other	1 849	8.5	7.5	8	7.3		1 616	8.6	7.5
Unknown	150	0.7	0.6	0.6	0.5		108	0.7	0.5
Percent with no high school diploma
<7	6 247	31.6	15.8	11	17.8	<.0001	5 784	30.6	26.7	<.0001
7-12.9	7 420	34.6	26.3	29.9	31.3		7 450	34.6	35.2
13-20.9	5 137	21.9	27.8	29.1	28.3		5 106	21.7	24.4
>21	3 080	10.7	29.2	29.2	21.6		2 622	11.8	12.4
Unknown	249	1.2	0.9	0.8	1		257	1.3	1.2
B symptoms present
Yes	4 139	16.6	31.2	28.7	21.6	<.0001	3 206	14.2	15.3	.0688
No	16 309	75.5	63.1	66	70.4		15 993	77.6	75
Unknown	1 685	7.9	5.7	5.4	8		2 020	8.3	9.7
Stage
I/II	8 574	40	29.5	30.7	40.1	<.0001	9 105	43.8	42.8	.0813
III/IV	11 675	51.7	61.7	61.1	49.9		9 904	44.6	47
Unknown	1 884	8.4	8.8	8.2	9.9		2 210	11.6	10.2
Comorbidities
0	19 152	88.6	84.9	79.4	73.1	<.0001	16 422	80.1	77	.0002
1	2 436	9.7	12.3	15.6	19.7		3 605	15.6	17.2
≥2	545	1.8	2.8	5	7.2		1 192	4.3	5.8
Initial treatment
Systemic	13 838	61	71.7	71.6	62.9	<.0001	11 805	54.2	55.9	.0959
None	7 629	35.7	26.9	25.6	35.5		8 890	43.3	41.7
Days from diagnosis to treatment
0-14	8 264	37.9	35.3	36.5	34	.0002	7 439	34.2	35.2	.0412
15-30	3 342	15.1	14.6	15.2	15.7		3 041	12.8	14.6
>30	6 437	28.4	34.1	32.1	30.1		5 748	28.1	26.9
Unknown	4 090	18.7	16	16.2	20.2		4 991	24.9	23.3